In the last trading session, 6.88 million Bioline Rx Ltd ADR (NASDAQ:BLRX) shares changed hands as the company’s beta touched 1.47. With the company’s per share price at $0.14 changed hands at $0.0 or 0.21% during last session, the market valuation stood at $19.57M. BLRX’s last price was a discount, traded about -1028.57% off its 52-week high of $1.58. When we look at Bioline Rx Ltd ADR’s average trading volume, we note the 10-day average is 20.55 million shares, with the 3-month average coming to 4.08 million.
Analysts gave the Bioline Rx Ltd ADR (BLRX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended BLRX as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Bioline Rx Ltd ADR’s EPS for the current quarter is expected to be 0.0.
Bioline Rx Ltd ADR (NASDAQ:BLRX) trade information
Instantly BLRX was in green as seen at the end of in last trading. With action -44.09%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -33.22%, with the 5-day performance at -44.09% in the red. However, in the 30-day time frame, Bioline Rx Ltd ADR (NASDAQ:BLRX) is -42.70% down. Looking at the short shares, we see there were 1.06 million shares sold at short interest cover period of 2.39 days.
Bioline Rx Ltd ADR (BLRX) estimates and forecasts
Data shows that the Bioline Rx Ltd ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -78.11% over the past 6 months, a 84.04% in annual growth rate that is considerably higher than the industry average of 16.20%. Year-over-year growth is forecast to reach 419.01% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 7.72M. 1 analysts are of the opinion that Bioline Rx Ltd ADR’s revenue for the current quarter will be 792k. The company’s revenue for the corresponding quarters a year ago was 4.8M and 6.86M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 60.80%. The estimates for the next quarter sales put growth at -88.45%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 21.53%. The 2025 estimates are for Bioline Rx Ltd ADR earnings to increase by 91.44%.
BLRX Dividends
Bioline Rx Ltd ADR is expected to release its next quarterly earnings report in February.
CVI HOLDINGS, LLC holds the second largest percentage of outstanding shares, with 1.126% or 0.82 million shares worth $0.46 million as of 2024-06-30.
With 39.99 shares estimated at $5714.0 under it, the former controlled 0.05% of total outstanding shares.
